Zoledronic Acid, a Fractured Root, and a Patient Asking for a Guarantee

Risk stratification. Risk factors present: intravenous zoledronic acid (a potent bisphosphonate), duration of four years (risk rises with duration, particularly beyond three years), age, and diabetes with HbA1c 7.4%. Protective factors: no active infection, no steroid use, no smoking, previous extraction healed normally, and a planned atraumatic procedure. Overall this is a moderate-risk situation - the absolute risk of MRONJ after a single extraction is low (commonly quoted in the range of well under 1% for oral bisphosphonates, higher but still low for IV therapy), but it is not zero, and she deserves that honesty.

Drug holiday. I would not unilaterally stop or delay her zoledronic acid. The evidence that a drug holiday reduces MRONJ risk is weak, bisphosphonates persist in bone for years so a short interruption does not meaningfully change the local concentration, and interrupting osteoporosis treatment carries its own fracture risk. The correct action is to consult her prescribing physician, share the planned procedure, and let that clinician decide about timing - many will proceed without interruption. Where timing can be chosen, avoiding the immediate post-infusion period is a reasonable preference, though the evidence for it is limited.

Can the tooth be retained? A vertical root fracture in a molar with a 9-mm pocket has no predictable restorative solution. Attempting to retain it risks chronic infection and progressive bone loss, which is itself a risk factor for MRONJ and would make later surgery harder. Extraction is the better option, planned and executed carefully rather than delayed until an acute infection forces an emergency.

Answer her fear directly: explain that MRONJ is uncommon, that the risk can be reduced by technique, and that a plan exists if it occurs - but a guarantee cannot honestly be given by anyone.

Before surgery.

• Confirm the multidisciplinary discussion with her physician and document it.
• Optimise diabetes control where possible and reinforce that HbA1c 7.4% is a modifiable risk factor.
• Chlorhexidine 0.12% rinse started before surgery and continued for about two weeks afterwards.
• Treat any coexisting periodontal inflammation first with gentle debridement so the surgical site is not inflamed.

During surgery.

• Atraumatic technique is the central principle: careful periosteal handling, no excessive raising of flaps, sectioning of the tooth to remove it in pieces rather than luxating a large root mass, and removal of sharp bone edges.
• Aim for primary closure with a tension-free flap; avoid leaving exposed bone.
• Copious irrigation and removal of all granulation tissue and any infected apical debris.
• Avoid elective bone recontouring or extensive ostectomy at the same visit.

Antibiotics. There is no strong evidence that prophylactic antibiotics prevent MRONJ, but many clinicians use a short perioperative course (e.g., amoxicillin or amoxicillin/clavulanate, with clindamycin as an alternative in penicillin allergy) when the socket is infected or closure is difficult. If used, document the rationale; do not present it as proven prevention.

After surgery.

• Review at 1–2 weeks, then at 4 and 8 weeks, with instructions to return immediately for non-healing, exposed bone, pain, or discharge.
• Continue chlorhexidine and gentle hygiene; avoid trauma from dentures or hard food.
• Emphasise that early reporting is what allows conservative management to succeed.

Consent as a conversation, not a form. Acknowledge her fear first: 'You have read about jaw death, and I want to explain what that actually means and what your real risk is.' Then cover, in plain language:

• The diagnosis and the alternative: the tooth is fractured and cannot be predictably saved; leaving it risks recurrent infection, which itself increases the risk of the bone problem.
• The specific risk: MRONJ is uncommon but possible; it is more likely with intravenous bisphosphonates and longer duration; the exact figure cannot be given for her individually.
• What reduces the risk: atraumatic surgery, chlorhexidine, good diabetes control, follow-up, and coordination with her physician.
• What happens if it occurs: most cases are managed conservatively with rinses, antibiotics if infected, and observation; surgery is reserved for refractory cases. It is not inevitably 'jaw death'.
• The limits of a guarantee: no clinician can guarantee any outcome. What can be promised is a careful plan, honest information, and close follow-up.

Document the discussion, her questions, and her decision. Offer written information and a follow-up appointment to discuss further if she wishes; proceeding on the day of an anxious first consultation is not mandatory.

If exposed bone and mucosal breakdown persist at 8 weeks: this meets the clinical definition of MRONJ (exposed bone or bone probeable through a fistula persisting beyond 8 weeks in a patient on antiresorptive therapy, with no radiation history or obvious metastasis). Then:

1. Stage the lesion (Stage 0–3) based on symptoms, bone exposure, and the presence of infection or pathological fracture.
2. Manage conservatively: chlorhexidine, analgesia, antibiotics only if there is secondary infection, and gentle debridement of loose sequestra - not aggressive resection.
3. Refer to oral and maxillofacial surgery and coordinate with her physician.
4. Avoid elective bone surgery and further extractions in the affected area; review regularly and document progression or healing.

Reassure her that most cases stabilise with conservative care, and keep her engaged in follow-up rather than losing her to anxiety-driven avoidance.